You are looking for a GeneSight alternative. Short answer: Gene2Rx covers the same core pharmacogenetic science that GeneSight uses (CPIC and FDA guidelines), works with the 23andMe or AncestryDNA data you may already have, does not require a doctor's order, and costs $5 to $49 instead of several hundred dollars. It also reports on more medications than GeneSight does, because GeneSight's coverage is deliberately focused on psychiatry. For the full side-by-side breakdown with feature-by-feature comparison, see our full Gene2Rx vs GeneSight comparison. The rest of this guide explains why people commonly look for an alternative to GeneSight and what to look for in any pharmacogenetic test.
Pharmacogenetic test results are not a diagnosis. They describe how your body processes medications, which is useful context for prescribing decisions. They are not a substitute for medical advice. Never start, stop, or change a medication based solely on a genetic test result. Discuss your results with your healthcare provider before making any change.
GeneSight must be ordered by a healthcare provider, typically a psychiatrist. If you do not have a psychiatrist, or your primary care doctor is not comfortable ordering pharmacogenetic testing, you cannot simply buy GeneSight yourself. This is the single most common reason people look for an alternative. Gene2Rx is direct-to-consumer, so you can order it for yourself without involving a prescriber. You can still share the results with your doctor afterward.
GeneSight's full list price runs into the thousands, though Myriad caps patient out-of-pocket responsibility at about $330 for most insured patients and offers financial assistance for those who qualify. If you are uninsured, or your insurance denies coverage because of diagnosis requirements, or you simply do not want to navigate insurance billing, the cost can still be a barrier. Gene2Rx starts at $5 and tops out around $49, with no insurance paperwork.
GeneSight's panel is built around psychiatric prescribing: antidepressants, antipsychotics, mood stabilizers, and ADHD medications. If you also want pharmacogenetic information for a statin, a blood thinner, a pain medication, a chemotherapy drug, an immunosuppressant, or an acid reflux medication, GeneSight will not cover it. Gene2Rx reports on 103 medications across every major drug class where CPIC or FDA guidelines apply.
If you have done 23andMe, AncestryDNA, MyHeritage, or whole-genome sequencing, your raw data already contains the variant calls needed for most pharmacogenetic interpretation. Paying for a new cheek-swab test to re-sequence the same variants is a duplication of work. Gene2Rx is specifically designed to extract pharmacogenetic insights from this existing data, without requiring a new sample.
All reputable pharmacogenetic tests analyze the same core drug-metabolizing genes using the same CPIC and FDA guidelines. The differences are in which medications are reported on, how results are formatted, cost, and accessibility, not in the underlying science.
The most clinically important pharmacogene. Metabolizes many antidepressants (paroxetine, venlafaxine, fluoxetine, amitriptyline), ADHD medications (atomoxetine, amphetamine), pain medications (codeine, tramadol), tamoxifen, and beta-blockers (metoprolol). About 5 to 10 percent of people of European descent are poor metabolizers and 1 to 2 percent are ultrarapid metabolizers.
Metabolizes several SSRIs (sertraline, escitalopram, citalopram), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. Poor metabolizer rates range from 2 to 15 percent depending on ancestry, and rapid or ultrarapid metabolizers represent another significant share of the population.
Metabolizes warfarin, phenytoin, celecoxib, and several NSAIDs. About 14 percent of people carry decreased-function variants. Most consequential for warfarin dosing, where small clearance differences translate into large dose differences.
Transports statins into liver cells. A common reduced-function variant is directly linked to statin-associated muscle pain. About 15 to 20 percent of people carry the variant. GeneSight does not include this gene; Gene2Rx does.
The key question for any pharmacogenetic test is whether it analyzes the genes relevant to your medications and presents the results in a way that is actionable for you and your clinician. The underlying biology is standardized. The delivery differs.
Pharmacogenetic testing is worth considering if you have struggled to find the right medication, if you are starting a medication with strong pharmacogenetic evidence (like clopidogrel after a stent, warfarin for anticoagulation, or capecitabine for chemotherapy), or if you simply want a one-time test that will inform prescribing decisions for the rest of your life. Your genetics do not change. A pharmacogenetic profile obtained today will still be valid 20 years from now.
Learn how genetics may affect your response to these related medications:
Both use the same CPIC and FDA pharmacogenetic guidelines as their clinical foundation. The practical differences: Gene2Rx is direct-to-consumer (no doctor order), costs $5 to $49 (versus several hundred with insurance or much more without), uses your existing 23andMe or AncestryDNA data, and covers 103 medications across all major drug classes instead of about 60 psychiatric-focused medications. For the full side-by-side see the Gene2Rx vs GeneSight comparison page.
Yes. 23andMe's raw data files contain genotype calls for most of the key pharmacogenetic variants in CYP2D6, CYP2C19, CYP2C9, SLCO1B1, VKORC1, and other clinically relevant genes. Services like Gene2Rx are specifically built to extract and interpret those variants from raw data files, using the same CPIC and FDA guidelines that any clinical pharmacogenetic test uses.
Most pharmacogenetic-aware clinicians will accept a Gene2Rx report as useful information because the underlying CPIC and FDA guidelines are the same ones they would reference from any other test. The report is traceable to specific CPIC guidelines and phenotype-level recommendations, which is the kind of information clinicians use to make dosing decisions. Bring the report to your appointment and ask how your clinician would incorporate it.
No. Both services analyze the same clinically relevant variants and report metabolizer phenotypes using the same guidelines. 'Accuracy' in pharmacogenetic testing means correctly calling the variants, and both services do that reliably. The differences are not about accuracy but about which medications are reported on, how results are displayed, how the service is delivered, and what it costs.
No. Gene2Rx is direct-to-consumer. You upload your genetic data, pay for the report tier you want, and receive the report. Sharing the report with your doctor afterward is strongly encouraged because pharmacogenetic information is most useful when combined with clinical judgment, but ordering the test does not require a prescriber.
Both GeneSight and Gene2Rx will report on CYP2D6 and CYP2C19 status, which are the genes that most affect antidepressant response. Gene2Rx will additionally report on medications outside the antidepressant class that your metabolizer phenotype might affect (pain medications, blood thinners, PPIs). If your clinician is specifically integrating GeneSight's color-tier report into psychiatric prescribing workflows, GeneSight's report format may fit their process better. Functionally, both will give you the information you need.
Find out how your DNA may influence your response to Sertraline and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator